July 2, 1997

The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2

Author Affiliations

From Washington University, St Louis, Mo (Dr Gutmann); University of North Carolina, Chapel Hill (Dr Aylsworth); University of Utah, Salt Lake City (Drs Carey and Viskochil); Boston Children's Hospital, Boston, Mass (Dr Korf); Sarah Lawrence College, Bronxville, NY (Dr Marks); Allegheny University of the Health Sciences, Pittsburgh, Pa (Dr Pyeritz); and Mt Sinai School of Medicine, New York, NY (Dr Rubenstein).

JAMA. 1997;278(1):51-57. doi:10.1001/jama.1997.03550010065042

Objective.  —Neurofibromatosis 1 and neurofibromatosis 2 are autosomal dominant genetic disorders in which affected individuals develop both benign and malignant tumors at an increased frequency. Since the original National Institutes of Health Consensus Development Conference in 1987, there has been significant progress toward a more complete understanding of the molecular bases for neurofibromatosis 1 and neurofibromatosis 2. Our objective was to determine the diagnostic criteria for neurofibromatosis 1 and neurofibromatosis 2, recommendations for the care of patients and their families at diagnosis and during routine follow-up, and the role of DNA diagnostic testing in the evaluation of these disorders.

Data Sources.  —Published reports from 1966 through 1996 obtained by MEDLINE search and studies presented at national and international meetings.

Study Selection.  —All studies were reviewed and analyzed by consensus from multiple authors.

Data Extraction.  —Peer-reviewed published data were critically evaluated by independent extraction by multiple authors.

Data Synthesis.  —The main results of the review were qualitative and were reviewed by neurofibromatosis clinical directors worldwide through an Internet Web site.

Conclusions.  —On the basis of the information presented in this review, we propose a comprehensive approach to the diagnosis and treatment of individuals with neurofibromatosis 1 and neurofibromatosis 2.